Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Why Branding is Pharma’s Most Undervalued Asset

ByMichael Christel,Ken Banta,Andy Milligan

April 10th 2026

The high cost of medicine in the United States is not a new phenomenon, but its root causes are complex and deeply embedded in the nation’s legal and regulatory architecture. . Credit: Stock.Adobe.com/Cagkan

The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation

ByPartha Anbil

April 3rd 2026

Data and Trust

ByMike Hennessy Jr.

March 17th 2026

Agentic AI and the Future of Commercial Excellence in Life Sciences

ByTanveer Nasir,Amber Pahare

March 12th 2026

AI has Redefined Healthcare Communication — and There’s No Opting Out

ByAlli Wiese

March 9th 2026

RxClub Awards 2008: Powerful & Simple

Articles in this issue

Newsletter

Related Content

Why Branding is Pharma’s Most Undervalued Asset

The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation

Data and Trust

Agentic AI and the Future of Commercial Excellence in Life Sciences

AI has Redefined Healthcare Communication — and There’s No Opting Out

Trending on PharmExec

Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market

Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?

Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs

Pharmaceutical Executive Daily: FDA Approves Breztri

Pharmaceutical Risks in the Strait of Hormuz